In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Circulating tumor cells (CTCs), shed by primary malignancies, function as" seeds" for distant
metastasis. However, it is still largely unknown how CTCs escape immune surveillance …

Our understanding of the function of the transcriptional regulators YAP and TAZ (YAP/TAZ)
in cancer is advancing. In this Review, we provide an update on recent progress in YAP/TAZ …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

CRISPR screens are a powerful source of biological discovery, enabling the unbiased
interrogation of gene function in a wide range of applications and species. In pooled …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …